ArticleFrontiers in pharmacology2026
Cost-effectiveness of disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial carcinoma in China.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Combination therapy with disitamab vedotin (DV) and toripalimab has been proven to significantly prolong progression-free survival (PFS) and overall survival (OS) first-line in patients with human epidermal growth factor receptor 2 (HER2) expressing, locally advanced or metastatic urothelial carcinoma (UC). The economic viability of this treatment strategy remains unclear. This study systematically evaluated the cost-effectiveness of DV plus toripalimab therapy versus platinum-based chemotherapy for these patients from the perspective of the Chinese healthcare system. Methods: Based on data from the RC48-C016 clinical trial, a Markov model was established to conduct a cost-effectiveness analysis of DV plus toripalimab versus platinum-based chemotherapy in patients with advanced or metastatic UC. Cost parameters were estimated by referencing published literature or local pricing models, while utility parameters were derived from published literature. The total cost, quality-adjusted life years (QALYs) for each group, and the incremental cost-effectiveness ratio (ICER) were calculated. The ICER was compared with China's willingness-to-pay (WTP) threshold to evaluate the economic efficiency of the two treatment strategies. Additionally, sensitivity analysis and scenario analysis were performed to verify the robustness of the established Markov model. Results: Patients in the chemotherapy group incurred a total cost of $59,329 with a corresponding gain of 1.78 QALYs. In comparison, patients in the DV plus toripalimab group had an incremental cost of $64,361 and an incremental QALY gain of 0.74, yielding an ICER of $86,954 per QALY. This value exceeded China's WTP threshold of $40,977 per QALY. Results of sensitivity and scenario analyses indicated that the cost of DV was the most influential factor on the ICER, and the model outputs were robust. For the combination therapy to be cost-effective, a 60% price reduction for both DV and toripalimab, or a 77% price reduction for DV alone, would be required. Conclusion: DV in combination with toripalimab is not cost-effective compared with platinum-based chemotherapy first-line in the treatment of patients with HER2-expressing locally advanced or metastatic UC in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.